title: [Terbinafine : Relevant drug interactions and their management].
abstract: The allylamine terbinafine is the probably most frequently prescribed systemic antifungal agent in Germany for the treatment of dermatomycoses and onychomycoses. According to the German drug law, terbinafine is approved for patients who are 18 years and older; however, this antifungal agent is increasingly used off-label for treatment of onychomycoses and tinea capitis in children. Terbinafine is associated with only a few interactions with other drugs, which is why terbinafine can generally be used without problems in older and multimorbid patients. Nevertheless, some potential interactions of terbinafine with certain drug substances are known, including substances of the group of antidepressants/antipsychotics and some cardiovascular drugs. Decisive for the relevance of interactions is-along with the therapeutic index of the substrate and the possible alternative degradation pathways-the genetically determined type of metabolism. When combining terbinafine with tricyclic antidepressants or selective serotonin reuptake inhibitors and serotonin/noradrenalin reuptake inhibitors, the clinical response and potential side effects must be monitored. Problematic is the use of terbinafine with simultaneous treatment with tamoxifen. The administration of potent CYP2D6 inhibitors leads to a diminished efficacy of tamoxifen because one of its most important active metabolites-endoxifen-is not sufficiently available. Therefore, combination of tamoxifen and terbinafine should be avoided. In conclusion, the number of substances which are able to cause clinically relevant interactions in case of simultaneously administration with terbinafine is clear and should be manageable in the dermatological office with adequate monitoring.
authors.affiliation: Apotheke, Abteilung Arzneimittelinformation & Klinische Pharmazie, Universitätsklinikum Leipzig - AöR, Liebigstr. 20, 04103, Leipzig, Deutschland. axel.duerrbeck@medizin.uni-leipzig.de.
authors.forename: A
authors.initials: A
authors.lastname: Dürrbeck
authors.affiliation: Labor für medizinische Mikrobiologie, Mölbis, Deutschland.
authors.forename: P
authors.initials: P
authors.lastname: Nenoff
mesh_terms: D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D003881:Dermatomycoses / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods*; D019317:Evidence-Based Medicine; D009281:Naphthalenes / Q000008:administration & dosage* / Q000009:adverse effects*; D000077291:Terbinafine; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine
keywords: Allylamine; Antidepressants; Antifungal agents; Cytochrom-P450; Serotonin reuptake inhibitors